{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Figarella-Branger D"],"funding":["Institut National du Cancer"],"pagination":["755-766"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11889709"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["27(3)"],"pubmed_abstract":["<h4>Background</h4>In the POLA cohort, 3 pathological groups of CNS WHO grade 3 oligodendroglioma IDH-mutant and 1p/19q co-deleted have been described: group 1 (high mitotic count only), group 2 (microvascular proliferation MVP and no necrosis), and group 3 (MVP and necrosis).<h4>Methods</h4>494 patients from the POLA cohort, with a median follow-up of 96 months were included. To identify the impact of the pathological groups and contrast enhancement (CE) in group 1 on overall survival (OS) or progression-free survival (PFS), survival curves were obtained (Kaplan-Meier method) and compared (log-rank test). The prognostic value of clinical factors and CDKN2A homozygous deletion HD were also tested. Multivariate analysis was performed.<h4>Results</h4>Survival analysis demonstrated that the p"],"journal":["Neuro-oncology"],"pubmed_title":["Reappraisal of prognostic factors in CNS WHO grade 3 oligodendrogliomas IDH-mutant and 1p/19q co-deleted: Lessons from the French POLA cohort."],"pmcid":["PMC11889709"],"funding_grant_id":["INCa_16828"],"pubmed_authors":["Appay R","Dehais C","Andraud M","Dhermain F","Mokhtari K","Seyve A","POLA network","Guillamo JS","Noel G","Cruel T","Adam C","Guillain N","Vandenbos-Burel F","Lhermitte B","Cohen-Moyal E","Marguet F","Forest F","Richard P","Younan N","Gaultier C","Desenclos C","Chiforeanu D","Rigau V","Rousseau A","Zemmoura I","Ghiringhelli F","Campone M","Blechet C","Diebold MD","Colin C","Khallil T","Loussouarn D","Bernier M","Parker F","Abad M","Faillot T","Meyronet D","Adle-Biassette H","Labrousse F","Bourg V","Carpiuc I","Gauchotte G","Colin P","Ricard D","Roger P","Milin S","Lopez S","Wager M","Khettab M","Touat M","Motso-Fotso MJ","Hamdan N","Djelad A","Cazals-Hatem D","Carpentier A","Vauleon E","Idbaih A","Carpentier C","Ducray F","Bielle F","Taillandier L","Uro-Coste E","Gueye EM","Seizeur R","Chinot O","Menei P","Aubriot-Lorton H","Langlois O","Figarella-Branger D","Bronnimann C","Tabouret E","Tortel MC","Maurage CA","Chotard G","Godfraind C","Quintin-Roue I","Joubert C","Bauchet L","Rousselot-Denis C"],"additional_accession":[]},"is_claimable":false,"name":"Reappraisal of prognostic factors in CNS WHO grade 3 oligodendrogliomas IDH-mutant and 1p/19q co-deleted: Lessons from the French POLA cohort.","description":"<h4>Background</h4>In the POLA cohort, 3 pathological groups of CNS WHO grade 3 oligodendroglioma IDH-mutant and 1p/19q co-deleted have been described: group 1 (high mitotic count only), group 2 (microvascular proliferation MVP and no necrosis), and group 3 (MVP and necrosis).<h4>Methods</h4>494 patients from the POLA cohort, with a median follow-up of 96 months were included. To identify the impact of the pathological groups and contrast enhancement (CE) in group 1 on overall survival (OS) or progression-free survival (PFS), survival curves were obtained (Kaplan-Meier method) and compared (log-rank test). The prognostic value of clinical factors and CDKN2A homozygous deletion HD were also tested. Multivariate analysis was performed.<h4>Results</h4>Survival analysis demonstrated that the p","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Mar","modification":"2026-06-04T13:34:52.868Z","creation":"2026-05-09T03:12:23.274Z"},"accession":"S-EPMC11889709","cross_references":{"pubmed":["39432559"],"doi":["10.1093/neuonc/noae221"]}}